Irinotecan liposomal(Jiangsu Hengrui Medicine)
- Generic Name
- Irinotecan liposomal(Jiangsu Hengrui Medicine)
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
Phase 1
Recruiting
- Conditions
- Advanced Pancreatic Cancer (Part 1)
- Interventions
- Drug: Irinotecan liposoma
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Dai, Guanghai
- Target Recruit Count
- 138
- Registration Number
- NCT06782685
- Locations
- 🇨🇳
Beijing, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Efficacy and Safety
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Target Recruit Count
- 120
- Registration Number
- NCT06383078
A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05425472
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath